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The origin of follicular bile acids in the human ovary 
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Bile acids (BA) are present in ovarian follicular fluid (FF) and have been linked to embryo 
development. However, information on the source of ovarian BA is scarce. Therefore, we aimed to 
explore local ovarian synthesis and BA transport from blood into FF. BA levels were determined in 
matching FF and serum from women who underwent in vitro fertilization. In vitro BA production by 
human mural (MCG) and cumulus granulosa cells (CGC) was measured by mass spectrometry. Gene 
and protein expression were quantified in human MCG and CGC and in human ovarian tissue by 
quantitative PCR and Western blot/immunohistochemistry, respectively. There was a significant 
correlation between the levels of BA in blood and FF (rs=0.186, P = 0.027). Interestingly, levels of FF 
BA were almost double those in blood (P < 0.001) with a higher percentage of primary BA, indicating 
that, in addition to passive diffusion, other sources of ovarian BA might exist. The key BA synthesis 
enzyme CYP7A1 was absent in MGC and CGC, and there was no evidence of BA production in vitro. 
Therefore, local ovarian BA production is unlikely. However, common BA importers (NTCP, ASBT) and 
an exporter (ABCC3) were identified in GC, theca cells, and the oocyte. In summary, these results 
suggest that passive and active transport of BA from blood into FF constitute sources of FF BA. 
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Prior to ovulation, oocytes develop in ovarian follicles. Each preovulatory follicle has an external, 
vascularized layer of theca cells and an avascular internal space that consists of granulosa cells (GC), 
the oocyte, and follicular fluid (FF) 
1
. GC are metabolically active cells that line the interior of the 
follicle (mural GC: MGC) and form a layer around the oocyte (cumulus GC: CGC). The proximity of the 
CGC to the oocyte is functionally important
2
. Indeed, oocyte maturation is regulated by the 
surrounding CGC 
3
, which provide most of its metabolic substrates 
4, 5
. Moreover, the oocyte 
regulates expansion of the CGC population, which in turn has been shown to impact fertility 
6
. Thus, a 
functioning relationship between CGC and oocyte is crucial for oocyte development. 
In the growing follicle, GC contribute to the accumulation of increasing amounts of FF that surround 
the oocyte. FF thus constitutes the natural environment of the oocyte during maturation. Moreover, 
alterations in its composition have been linked to oocyte development and embryo quality 
7-9
. The 
composition of FF is determined by two main factors: passive or active transport of metabolites from 
the systemic circulation and local production by GC. Passage of metabolites from blood into FF seems 
to be size-dependent, with small components passing freely and larger ones selectively or facilitated 
by transporters, if at all 
1
. Therefore, alterations in the maternal blood composition of smaller 
molecules are expected to be to a certain extent reflected in FF, the microenvironment of the 
developing oocyte 
10
. With regards to local production, GC are capable of modifying the composition 
of FF by secreting or degrading metabolites. For example, in addition to local steroid production
11
, 
human GC were demonstrated to secrete very-low density lipoproteins (VLDL) and higher levels of FF 
VLDL were correlated with better in vitro fertilization (IVF) outcomes 
12
. Thus, the final FF 
composition of the mature follicle is a reflection of systemic maternal and local follicular metabolism. 
Bile acids (BA) are steroid compounds that are classically involved in fat and vitamin absorption in the 
gut, but are increasingly recognized for their endocrine roles, such as in glucose and lipid metabolism 
13, 14
. BA production occurs via two pathways: the classic (neutral) and the alternative (acidic) 
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. To preserve the BA pool, loss of BA is prevented by active reuptake from the digestive 
tract into the blood stream via specialized transporters in the intestine and liver 
16
. Importantly, BA 
have been shown to be present in FF and are linked to embryo development in IVF, indicating that BA 
may have biological relevance for oocyte maturation 
8
. Hence, it is conceivable that alterations in the 
FF BA pool may have an impact on the oocyte and, consequently, on embryo development. However, 
the origin of BA in FF has not been clarified. In addition to simple diffusion from blood into FF, other 
sources of BA, such as local production and active transport, could play a role 
17
. The present study 
thus aimed to delineate the origin of ovarian BA with a focus on the two possibilities, local 
intrafollicular synthesis and import from the blood compartment.  
 
Materials and methods 
Follicular fluid and serum collection 
Follicular fluid and serum from patients undergoing modified natural cycle (MNC)-IVF at the 
University Medical Center Groningen (UMCG) in Groningen, the Netherlands, were collected during a 
multicenter cohort study on the outcomes of MNC-IVF 
18
. Our group has previously reported on BA 
levels in a subset of these samples consisting of only samples from the first IVF cycle of a patient 
8, 18
. 
For the present study, samples from a subsequent IVF cycle were used. Details on patient inclusion 
and study protocol have been previously published 
8, 18
. A universal consent form was signed by all 
patients and their confidentiality was protected during the study by assigning patients and samples 
untraceable codes. None of the patients objected to the use of their so-called waste material (such 
as FF, GC, and surplus serum), which routinely becomes available during patient care and would 
otherwise be discarded. Fasted blood was drawn on the morning of oocyte retrieval and surplus 
serum was stored under the respective study code at -20 °C. After oocyte collection, the remaining FF 
was centrifuged for 20 min at 300 g and the supernatant was stored under the respective study code 
at -20 °C. 
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For the current study, FF and matching blood samples fulfilling the following criteria were used: FF 
was free of blood contamination upon visual inspection, no or one oocyte was retrieved, only one 
mature follicle was detected by ultrasound at ovum pickup.  
Ethical approval from the Institutional Review Board was requested but waived, since materials were 
anonymized, and patients had signed the universal consent form. 
 
Modified natural cycle – in vitro fertilization procedure and collection of follicular fluid for bile acid 
analysis 
The MNC-IVF procedure has been described in detail previously 
18, 19
.In contrast to classic 
hyperstimulation IVF, where multiple dominant follicles develop in each cycle, in MNC-IVF only one 
dominant follicle develops and its contents are retrieved at ovum pickup. Consequently, the 
composition of the FF can be accurately compared to that of the matching blood sample. 
In short, when the diameter of a natural growing ovarian follicle (measured by vaginal 
ultrasonography) reached 14 mm, daily injections of 0.25 mg GnRH antagonist and 150 IU 
recombinant FSH were started. When the diameter of the dominant follicle reached a minimum 18 
mm and/or serum estradiol levels exceeded 0.8 nmol/L, 10 000 IU hCG was administered to prevent 
ovulation. Approximately 34 h later the oocyte was retrieved with a single-lumen aspiration needle 
and without flushing of the follicle. The oocyte was inseminated following standard procedure. If 
macroscopic blood contamination was absent, the FF was centrifuged for 20 minutes at 300 g and 
the supernatant was stored at -80 
o
C for later analysis. 
 
Controlled ovarian hyperstimulation – in vitro fertilization procedure and collection of granulosa cells  
The controlled ovarian hyperstimulation (COH)-IVF procedure has been described in detail elsewhere 
20
. In short, on day 23 of the previous menstrual cycle or during the use of oral contraceptives 
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patients were started on a hormonal down-regulation protocol with daily subcutaneous triptorelin 
0.5 mg GnRH analog and human menopausal gonadoprophin 150 to 225 IU up until the day of hCG 
injection. When the diameter of at least three dominant follicles reached a minimum 18 mm, 5 000 
IU hCG was administered for final maturation of the follicle and oocyte. Approximately 36 h later the 
oocytes were retrieved with a single-lumen aspiration needle.  Cumulus aggregates (CGC) were 
manually separated from the oocyte and used for experiments. After removal of cumulus-oocyte 
complexes, the FF was saved in 50 mL Falcon tubes (Corning, Reynosa, Mexico) at 37.5 
o
C and 5% CO2 
until they could be used for isolation of MGC later the same day. Only the laboratory technician and 
the fertility physician that were involved in the clinical procedure were aware of the identity and 
characteristics of the patient, but not the researchers. 
 
Cumulus and mural granulosa cell isolation and culture 
Primary MGC and CGC were obtained from pre-ovulatory follicles from women undergoing 
controlled ovarian hyperstimulation-IVF (COH-IVF) at the UMCG. CGC were manually separated from 
the cumulus-oocyte complex and washed once in Hank’s Balanced Salt Solution (HBSS) (Life 
Technologies, USA) before being brought into culture or stored for further analysis. For the isolation 
of MGC, FF was centrifuged for 5 min at 400 g followed immediately by 5 min at 500 g. Red blood 
cells were removed by layering the cell pellet on a 40% Percoll (GE Healthcare, Uppsala, Sweden) 
solution followed by centrifugation for 10 min at 550 g. The suspension of GC was gently pipetted out 
and washed twice in HBSS to remove the Percoll solution. Both CGC and MGC were either stored for 
later analysis or brought into culture. In the latter case, both cumulus and MGC were first incubated 
in trypsin for 3 minutes at 37 
o
C followed by dispersion of potential clumps by passage through a 40 
μm cell strainer (Corning, Durnham, NC).  
Finally, primary CGC and MGC were plated in 12-well plates (Corning, Kennebunk, ME) at a density of 
300 000 cells/well and were left to attach for two days in basal medium (Dulbecco’s Modified Eagle 
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Medium/Nutrient Mixture F-12 [Gibco, Paisley, UK] supplemented with 10% fetal calf serum [FCS] 
[Lonza, Verviers, Belgium] and 1% penicillin/streptomycin/amphotericin B [Lonza, Walkersville, MA]) 
at 37 
o
C and 5% CO2. The medium was refreshed after two days and then daily until the culture was 
devoid of red blood cells upon visual inspection (on average four days). Thereafter, the cells were 
cultured for 63 hours in medium with either 0.34 mmol/L LDL cholesterol, 0.34 mmol/L HDL 
cholesterol or the equivalent volume of phosphate-buffered saline (PBS; Gibco, Paisley, UK). FCS was 
not added to this medium as it contains BA. LDL and HDL were isolated by sequential 
ultracentrifugation (1.019 < d < 1.063 and 1.063 < d < 1.21, respectively) from plasma of healthy male 
volunteers. HepG2 cells (a hepatoma cell line) and empty wells were used as positive and negative 
controls for each condition, respectively.  
 
Bile acid measurements  
In blood and FF, measurement of total BA were conducted using an enzymatic fluorimetric assay and 
by liquid chromatography-mass spectrometry (LC-MS) as previously described 
8
. In cell culture 
supernatants and cell lysates, BA were measured by LC-MS as previously described 
8
.   
 
Protein measurement 
Total protein levels were measured in matched FF and serum using the BCA Protein Assay Kit (Pierce, 
Rockford, IL) following the instructions provided by the manufacturer. 
 
Isolation of RNA and measurement of mRNA levels by quantitative real-time PCR 
Total RNA was obtained from freshly isolated MGC and CGC and from healthy human livers using TRI 
Reagent (Sigma, St. Louis, MO) and quantified with a Nanodrop spectrophotometer (Nanodrop 
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2000c, Thermo Scientific). Complementary DNA was synthesized from 1 μg of RNA using Moloney-
Murine Leukemia Virus reverse transcriptase (Invitrogen, Carlsbad, CA). Quantitative real-time PCR 
analysis was performed on a Real-Time PCR system (StepOnePlus, Applied Biosystems). Primers and 
fluorogenic probes (Table 1) were designed with the Primer Express software (Thermo Fisher 
Scientific) and synthesized by Eurogentec (Seraing, Belgium). Gene expression levels were normalized 
to the housekeeping gene peptidylprolyl isomerase G and calculated using the delta-Ct method.  
 
Western Blotting 
Western blots for Na
+
/Taurocholate Cotransporting Polypeptide (NTCP), apical sodium-dependent 
bile acid transporter (ASBT), ATP-Binding Cassette Sub-Family C Member 4 (ABCC4) and ATP-Binding 
Cassette Sub-Family C Member 3 (ABCC3) were performed on primary human MGC and CGC pooled 
from several patients. Protein was resolved by SDS-PAGE electrophoresis and subsequently blotted 
onto nitrocellulose (Trans-Blot Turbo Transfer Pack, Biorad, Hercules, CA). The proteins were 
visualized using NTCP antibody (kindly provided by Prof. Dr. Bruno Stieger, University Hospital Zurich, 
Zurich, Switzerland; raised in rabbit; dilution 1:500), ASBT antibody (kindly provided by Prof. Paul A. 
Dawson, Wake Forest University School of Medicine, Winston-Salem, NC; raised in rabbit; dilution 
1:10000), commercially available ABCC4 antibody (M4I-10, NBP1-42339, Novus Biologicals, MN; 
raised in rat; dilution 1:200) and commercially available ABCC3 antibody (sc-5776, C-18, Santa Cruz 
Biotechnology, Santa Cruz, CA; raised in goat; dilution  1:500), followed by the appropriate HRP-
conjugated secondary antibody (goat anti-rabbit [P0448, Dako, Heverlee, Belgium], rabbit anti-goat 
[P0449, Dako, Heverlee, Belgium], and goat anti-rat [HAF005, R&D Systems, MN]). 
 
Immunohistochemistry 
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Anonymized ovarian tissue from carriers of the BRCA mutation who underwent preventive 
oophorectomy was used. The tissue was fixed in formalin, embedded in paraffin, and sectioned into 
3 μm slides. Prior to staining, paraffin was removed by immersion of the slides in xylol solution, 
followed by washing in ethanol. For antigen retrieval, either magnesium citrate (ASBT and ABCC4), 
EDTA (NTCP), or Tris/EDTA buffer (ABCC3) was used. To reduce endogenous peroxidase activity, the 
slides were incubated in hydrogen peroxide solution for 30 minutes. The slides were then incubated 
for one hour at room temperature in primary antibody dissolved in 1% BSA/PBS. The following 
dilutions were used: NTCP 1:500, ASBT 1:200, ABCC4 1:100 (see above), and ABCC3 1:100 (sc-5774, 
H-16, Santa Cruz Biotechnology, Santa Cruz, CA; raised in goat). Thereafter, they were incubated with 
secondary and tertiary goat anti-rabbit antibodies (P0448, Dako, Heverlee, Belgium), rabbit anti-goat 
(P0449, Dako, Heverlee, Belgium), and rabbit anti-goat antibodies (P0450, Dako, Heverlee, Belgium) 
diluted 1:100 in 1%BSA with 1% corresponding serum solution prepared in PBS. The order of these 
antibodies was determined by the nature of the primary antibody. The slides were then incubated 
for 10 minutes in 3,3’-diaminobenzidine and counterstained with hematoxylin. Finally, the slides 
were dehydrated and mounted. 
 
Statistical analysis 
Results of the measurements of BA in FF and matched serum and of measurements of total protein 
in FF and serum were expressed as median [interquartile range]. Their correlations were expressed 
as Spearman’s r. For BA measurements in matched FF and serum, the levels were compared 
statistically using multilevel generalized estimating equations and the results were presented as odds 
ratio (95% confidence interval)). For protein measurement in matched FF and serum, the levels were 
compared statistically using Wilcoxon Signed Ranks test. Gene expression levels in CGC and MGC 
were compared statistically using the independent samples t-test if the values were normally 
distributed or the Mann-Whitney U test if the values were not normally distributed. A P-value <0.05 
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Passive diffusion of bile acids from blood into follicular fluid 
Total bile acid (TBA) levels were measured in FF and matching serum from 142 MNC-IVF procedures 
corresponding to 131 unique patients. A summary of cycle characteristics can be found in 
Supplementary Table S1. There was a weak positive correlation between TBA in serum and that in 
blood (rs=0.186, P = 0.027; Fig 1), and secondary bile acids were present in FF (deoxycholic acid 
derivatives [DCA]: 0.72 [0.39 to 1.19] μmol/L, n=139). Nonetheless, TBA levels were consistently 
about two-fold higher in FF compared to matching serum samples (10.10 [8.38 to 11.93] versus 5.89 
[4.15 to 7.88] μmol/L, OR 58.01 (31.05 to 108.40), P < 0.001; Fig. 2) and primary BA were more 
abundant in FF than in matched serum (mean of 73% versus 60% of total BA, P < 0.001).  
To study whether the higher levels of FF BA may be related to a different protein composition of FF 
as compared to serum, total protein levels were measured in FF and matched serum samples from 
10 individual patients for which total BA measurements were available. The levels of protein in FF 
were significantly lower than those in matched serum (56.16 [51.86 to 59.25] mg/mL versus 69.83 
[67.54 to 76.32] mg/mL, P = 0.005). Moreover, there was no correlation between protein levels and 
total BA in FF (rs=-0.006, P = 0.987). 
 
Local ovarian bile acid production  
To study whether BA are locally produced in the ovaries, mRNA expression of key genes involved in 
BA production and metabolism was measured in freshly isolated MGC (nine individual patients) and 
CGC (eight individual patients) (Fig 3). For the BA production enzymes, healthy human livers served 
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as positive control (n=4). Prior to all analyses on primary MGC and CGC, the presence of anti-
Muellerian hormone type-2 receptor (MISR-II, markers specific for GC) and steroidogenic activity (ie, 
estrogen production upon induction with follicle stimulating hormone and androstenedione) of the 
isolated primary cells was confirmed (data not shown). Gene expression of CYP7A1 could not be 
detected in either MGC or CGC, indicating that the classical pathway of BA production is not present. 
Very low level mRNA expression of CYP8B1, CYP27A1, and CYP7B1 was inconsistently detected in 
MGC and CGC, also making it highly unlikely that there is a discernible, substantial de novo synthesis 
of BA via the alternative pathway in the ovary. Nonetheless, the nuclear receptors Farnesoid X 
Receptor (FXR), Retinoic Acid Receptor (RXR)-alpha, Liver X Receptor (LXR)-alpha, and Liver Receptor 
Homolog 1 (LRH1) as well as the G-Protein coupled bile acid receptor TGR5 were present in both cell 
types (Figure 4, Supplementary Table S2). The level of mRNA expression of FXR, RXR-alpha, LXR-
alpha, and LRH1 was hereby significantly higher in CGC than in MGC (P = 0.023 for FXR, P < 0.001 for 
all other).  
To further formally test the concept of de novo synthesis of BA via the alternative pathway in the 
ovary, MGC and CGC were cultured in medium without or with added lipoproteins as a substrate for 
BA synthesis (0.34 mmol/L LDL or 0.34 mmol/L HDL). BA content of cell supernatants and lysates was 
measured after 63 hours. In over 10 individual experimental repeats, BA could never be detected in 
any appreciable amounts in GC cultures (medium and cells) but were consistently present, though in 
low amounts, in material from HepG2 cultures.  
 
Active transport of bile acids from blood into follicular fluid  
To explore the possibility of active transport of BA from blood into FF,  mRNA expression studies of 
common BA importer (NTCP, ASBT, OATP1B1, OATP1B3) and exporter (Organic Solute Transporter 
Subunit alpha [OST-alpha], Organic Solute Transporter Subunit beta [abcb11 
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], ATP Binding Cassette Subfamily B Member 11 [ABCB11], ABCC3, ABCC4) proteins were performed 
in freshly isolated GC, harvested from FF from COH-IVF procedures. NTCP, ASBT, OST-alpha, ABCC3, 
and ABCC4 transcripts were present at varying levels in MGC and CGC (Fig. 5, Supplementary Table 
S2). The level of gene expression of ABCC3 was significantly higher in CGC as compared to MGC (P  < 
0.001). For NTCP, ASBT, OST-alpha, and ABCC4 there was no significant difference in the levels of 
gene expression between the two granulosa cell types. OST-beta and ABCB11 expression was below 
detection level in both cell types (data not shown). Since OST-alpha is only functional in the presence 
of OST-beta 
21
, protein expression of OST-beta was not studied.   
Next, protein expression of the above-mentioned transporters was studied (Fig. 6). Freshly isolated 
MGC and CGC from multiple patients were pooled and protein expression was assessed by Western 
blotting. Immunohistochemistry was performed on paraffin-embedded human ovarian tissue. In 
tertiary follicles, the BA importers ASBT and NTCP were present in both theca and MGC, and NTCP 
was additionally detected in CGC. The organic anion exporter ABCC3 was present in theca cells, MGC 
and CGC. ABCC3 expression could not be confirmed by Western blot of MGC. The presence of the BA 
exporter ABCC4 was confirmed in Western blots of CGC and MGC, but not in immunohistochemical 
staining of ovarian tissue. Finally, in immunohistochemistry of primary and primordial follicles, NTCP 
and ABCC3 were present in GC, whereas ASBT was absent. Finally, all three transporters were also 
clearly detectable in the oocyte.  
 
Discussion 
The results of the present study suggest that BA present in FF in higher amounts as compared to 
serum likely reach the FF from the systemic circulation by passive diffusion and active transport. 
Conversely, in human ovarian granulosa cells, local BA production is highly unlikely to occur. To our 
knowledge, this is the first report of BA transporters being present in ovarian follicles. 
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The BA synthesis pathway is traditionally thought to be exclusively present in the liver. However, a 
previous microarray study in human GC from hyperstimulation-IVF suggested that components of the 
classical and alternative pathway of BA synthesis are present in human CGC 
17
. In the current study, 
primary BA were two-fold more abundant in FF than in serum, indicating that local production may 
take place. Moreover, in partial agreement to previous work
17
, mRNA expression  of certain BA 
synthesis enzymes of the alternative pathway (namely CYP27A1 and CYP7B1) was found, although 
only very weak and inconsistent. However, physiological relevance could not be confirmed, since GC 
did not produce BA in any of the applied conditions. In addition, mRNA expression of CYP7A1, the key 
enzyme of the classical pathway, was completely absent. Combined, these data make it highly 
unlikely that BA are being locally produced in the ovary. The cause of this discrepancy between 
previous results and ours is unclear, but it may be related to differences in culture conditions 
17
. In 
the present study, FCS was not added to the culture medium, as this contains BA and may thus bias 
the results. 
Instead of local synthesis, our results suggest that ovarian BA are being passively and actively 
transported into FF. To enter the FF, blood components must pass through the blood-follicular 
barrier (BFB) composed of, from the exterior to the follicle, a vascular wall (endothelium and 
basement membrane), theca cells, follicular basement membrane, and GC 
1
. Passage of molecules 
from blood into FF is size- and charge-dependent 
1
. BA are small compounds that are predominantly 
present in blood bound to albumin and lipoproteins 
22
. With regards to the former, 
immunohistochemical studies have shown albumin to be present in the structures composing the 
BFB and the follicular antrum, suggesting that it passes unhindered from blood into FF 
10
. As for the 
latter means of transport, high density lipoproteins are the sole type of lipoproteins present in FF 
23
. 
Given their small size, they are assumed to originate from blood by diffusion across the BFB 
24
. 
Indeed, there was a positive correlation between BA in FF and those in blood, supporting the concept 
of passive diffusion. This is further reinforced by the presence of secondary BA in FF, since secondary 
BA originate from the modification by intestinal bacteria, which are not expected to be present in FF. 
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In conclusion, BA are likely to pass unhindered through the BFB as cargo of serum proteins, such as 
albumin, and possibly also high density lipoproteins. However, the much higher levels of FF BA as 
compared to blood (which is in agreement with the work of Smith et al 
17
) and the lack of a 
correlation between protein levels and BA levels in FF already suggest that facilitated transport, in 
addition to diffusion, takes place. The relative overabundance of BA importers (NTCP and ASBT) over 
exporters (ABCC3) found in the present study may explain BA accumulation in FF. In the present 
study, we have focused on the most common BA transporters and it cannot be excluded that other, 
less well-known importers and exporters may also be present in ovarian follicles. Since active 
transport is not formally shown in the current study, studies quantifying the relative transport 
capacities of each transporter in and out of FF would be interesting and additive to the current work. 
However, these are technically very challenging to perform and virtually impossible to carry out in 
humans. Finally, it should be mentioned that blood BA concentrations show diurnal variations, ie, are 
higher after ingestion of a meal. Since blood was collected under fasting conditions, high FF BA 
concentrations may in part reflect an earlier exposure to high serum BA concentrations. 
Accumulation of BA in FF during oocyte development and the presence of BA transporters in the 
oocyte as well as of a signaling system responsive to bile acids in the follicular environment argue in 
favor of a biological function of ovarian BA in human reproduction. Over the past decade there has 
been extensive research indicating that BA are more than just mere detergents, and also fulfill 
important endocrine functions. Indeed, they are involved in the regulation of glucose and lipid 
metabolism, immunity, and gut microbiota function via nuclear receptors such as FXR and TGR5 
13
. 
Moreover, BA seem to be involved in fertility and programming of offspring health. Ursodeoxycholic 
acid derivatives in human FF are associated with the development of top quality embryos 
8
. In 
animals, tauroursodeoxycholic acid has been shown to reduce apoptosis of mouse and pig embryos 
and to increase the implantation and live-birth rate in mice 
25-27
. In male rodents, supplementation of 
the diet with cholic acid results in reduced fertility, altered sperm methylation patterns, and 
increased perinatal mortality as well as metabolic changes of the surviving pups, effects that seem to 
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be mediated by TGR5 
28, 29
. Despite emerging studies on the possible mechanistic function of BA in 
animals, knowledge on BA in human reproduction is scarce and difficult to obtain due to ethical 
concerns regarding research with gametes and embryos.  
One of the strengths of this work is the study of two different types of human GC, CGC and MGC. 
Moreover, as to the best of our knowledge, we are the first to demonstrate the presence of the 
classic BA transporters NTCP and ASBT outside hepatocytes and ileocytes, respectively. However, the 
present study also has points that should be approached cautiously. Firstly, it cannot be excluded 
that the freshly isolated GC may have been contaminated with other types of cells (eg, vaginal 
epithelial cells, ovarian epithelial cells, ovarian stromal cells, theca cells) that may have affected the 
results of protein detection and would thus explain the discrepancies between the Western Blot and 
immunohistochemistry results. For example, cancerous epithelial ovarian cells have been previously 
shown to express ABCC4 
30
. In GC cultures, however, the majority of cells stained positive for MISR-II, 
indicating that, at least in cultures, contamination with other cells was minimal. Secondly, the FF is 
naturally rich in steroid hormones. In the present study, gonadotrophins stimulating steroid hormone 
production were not added to the culture medium, which may alter the functioning of the GC. 
However, the steroidogenic capacity of the cultured cells was intact, indicating that the cultivated 
cells were vital.   
In summary, the results of the present study suggest that BA likely reach ovarian follicles by both 
passive and active transport from the blood compartment. Further studies are warranted to gain 
insight into the regulation of BA transport from blood into FF and into a potential impact of 
dysfunctional transport on reproductive physiology. Moreover, changes in blood BA composition 
may possibly impact FF BA composition, which would enable lifestyle and pharmacological 
interventions to prevent and treat infertility. 
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Figure 1. Relationship of total bile acid levels in follicular fluid and in matching blood. Solid black line 
represents the best fitting line for the relationship between total bile acids in blood and in follicular 
fluid. rs=0.186, P = 0.027. 
 
Figure 2. Comparison of total bile acid levels in follicular fluid and in matching blood. ***P < 0.001. 
 
Figure 3. mRNA expression of key enzymes for bile acid production in mural and cumulus granulosa 
cells and human livers. CGC – cumulus granulosa cells, MGC – mural granulosa cells.  
 
Figure 4. mRNA expression of bile acid responsive receptors in mural and cumulus granulosa cells. 
CGC – cumulus granulosa cells. MGC – mural granulosa cells. *P < 0.05. ***P < 0.001.  
 
Figure 5. mRNA expression of common transport proteins involved in the import (upper row) and 
export of bile acids (lower row). CGC – cumulus granulosa cells, MGC – mural granulosa cells. ***P < 
0.001. 
 
Figure 6. Protein expression of the bile acid importers NTCP and ASBT and the bile acid exporter 
ABCC3 in cell lysates of human primary cumulus and mural granulosa cells (upper row: Western blot) 
and in ovarian tissue (middle row: immunohistochemical staining of tertiary follicles, scale bar 
represents 500 µm; lower row: immunohistochemical staining of primordial and primary follicles, 
scale bar represents 50 µm). CGC – cumulus granulosa cells, MGC – mural granulosa cells. 
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Table 1. Primer sequences. 
Gene name Sequence 
PPIG Forward: 5’- TGGAGCCATGGGAATAAAGGT - 3’ 
Reverse: 5’- CTCTTCCAGCAGGTTGATTGTTAAT - 3’ 
Probe: 5’ - CAACGTCCTCGATGTTTTTTTGACATTGCC – 3’ 
CYP7A1 Forward: 5’ - TCAGCTTGGAAGGCAATCCTAT - 3’ 
Reverse: 5’ - AGCCTCAGCGATTCCTTGATTA - 3’ 
Probe: 5’ - CTGGCAGGTCATTCAGTTCTGCTTGACTC - 3’ 
CYP8B1 Forward: 5’ - CCTGAGCTTGTTCGGCTACAC - 3’ 
Reverse: 5’ - TGCGGAACTCCATGAATAACTCTC- 3’ 
Probe: 5’ - CCTGTAGCAGGTCCTGCTCCTTGTCCTT - 3’ 
CYP27A1 Forward: 5’ - TGCGGGCAGAGAGTGCTT - 3’ 
Reverse: 5’ - ACAGGATGTAGCAAATAGCTTCCA - 3’ 
Probe: 5’ - CAGGTGTCGGACATGGCTCAACTCTTCT - 3’ 
CYP7B1 Forward: 5’ - CTTGAAATAGGAGCACATCATTTAGG- 3’ 
Reverse: 5’ - GATAATACATTGCCCAGAACATAGTTG - 3’ 
Probe: 5’ - CTCTGGGCCTCTGTGGCAAACACTATTC - 3’ 
FXR Forward: 5’ - AGGGGTGTAAAGGTTTCTTCAGGA- 3’ 
Reverse: 5’ - ACACTTTCTTCGCATGTACATATCCAT- 3’ 
Probe: 5’ - TTGCCCCCGTTTTTACACTTGTACACAGC- 3’ 
RXR-alpha Forward: 5’ - GCAAACATGGGGCTGAACC - 3’ 
Reverse: 5’ - GCTGCTTGGCAAATGTTGGT - 3’ 
Probe: 5’ - CAGCTCGCCGAACGACCCTGTC - 3’ 
LXR-alpha Forward: 5’ - CTTGCTCATTGCTATCAGCATCTT - 3’ 
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Reverse: 5’ - ACATATGTGTGCTGCAGCCTCT - 3’ 
Probe: 5’ - TCTGCAGACCGGCCCAACGTG - 3’ 
LRH-1 Forward: 5’ - CAGAGAACTTAAGGTTGATGACCAA - 3’ 
Reverse: 5’ - GGTAAATGTGGTCGAGGATTAAGAG- 3’ 
Probe: 5’ - TCACTCCAGCAGTTCTGAAGCAGCTTCA - 3’ 
TGR5 Forward: 5’ - CGTCTACTTGGCTCCCAACTTC - 3’ 
Reverse: 5’ - GGCCTCAGGACTGCCATGTA - 3’ 
Probe: 5’ - CTCTCCCTGCTTGCCAACCTCTTGC - 3’ 
VDR Forward: 5’ - CCGCATCACCAAGGACAAC - 3’ 
Reverse: 5’ - TCATCTGTCAGAATGAACTCCTTCA - 3’ 
Probe: 5’ - AGGCCTGCCGGCTCAAACGC - 3’ 
PXR Forward: 5’ - ACATGCTGAAGAAGCTGCAGCT - 3’ 
Reverse: 5’ - GGCGGTCTGGGGAGAAGA - 3’ 
Probe: 5’ - ATGGCCTGCATCAGCACATACTCCTCC - 3’ 
CAR Forward: 5’ - ACCGACCTGGAGTTACCCAGA - 3’ 
Reverse: 5’ - CTTCGCATACAGAAACCGATCC - 3’ 
Probe: 5’ - CTTTGCAGAGTCAGTGCCATCTCCTCTTG - 3’ 
FGFR4 Forward: 5’ - TGTGCAAGGTGTACAGCGATG - 3’ 
Reverse: 5’ - TATTGATGTCTGCAGTCTTTAGGACTT - 3’ 
Probe: 5’ - CGTCATCAACGGCAGCAGCTTCG - 3’ 
FGF19 Forward: 5’ - ATGCAGGGGCTGCTTCAGTA - 3’ 
Reverse: 5’ - AGCCATCTGGGCGGATCT - 3’ 
Probe: 5’ - TCCTCGAAAGCACAGTCTTCCTCCG - 3’ 
KLB Forward: 5’ - AATGGCTGGTTCACAGACAGTC - 3’ 
Reverse: 5’ - TCATCTAACCTTATTGCTTGAAGCA - 3’ 
Probe: 5’ - ACCACGGCCATCTACATGATGAAGAATTTC - 3’ 
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NTCP Forward: 5’ - TGATATCACTGGTCCTGGTTCTCA - 3’ 
Reverse: 5’ - GCATGTATTGTGGCCGTTTG - 3’ 
Probe: 5’ - TCCTTGCACCATAGGGATCGTCCTCA - 3’ 
ASBT Forward: 5’ - CACGCAGCTATGTTCCACCAT  - 3’ 
Reverse: 5’ - GAGCGGGAAGGTGAATACGA - 3’ 
Probe: 5’ – CAGCTCTCCTTCACTCCTGAGGAGCTC A - 3’ 
OST-alpha Forward: 5’ - GGTGAGCAGAACATGGGAGC - 3’ 
Reverse: 5’ – ATGGAGGGCTGTAGGGCAGT - 3’ 
Probe: 5’ - AAATTTGCTCTGTTCCAGGTTCTCCTCATCC - 3’ 
OST-beta Forward: 5’ – CAGGAGCTGCTGGAAGAGAT - 3’ 
Reverse: 5’ - GACCATGCTTATAATGACCACCA - 3’ 
Probe: 5’ - CGTGTGGAAGATGCATCTCCCTGGAATCATTC - 3’ 
ABCB11 Forward: 5’ - ACATGCTTGCGAGGACCTTTA - 3’ 
Reverse: 5’ – GGAGGTTCGTGCACCAGGTA - 3’ 
Probe: 5’ - CCATCCGGCAACGCTCCAAGTCT - 3’ 
ABCC3 Forward: 5’ - GCCATCGACCTGGAGACTGA - 3’ 
Reverse: 5’ - GACCCTGGTGTAGTCCATGATAGTG - 3’ 
Probe: 5’ - CATCCGCACCCAGTTTGATACCTGCAC - 3’ 
ABCC4 Forward: 5’ - AAGTGAACAACCTCCAGTTCCAG - 3’ 
Reverse: 5’ - GGCTCTCCAGAGCACCATCT - 3’ 
Probe: 5’ - CAAACCGAAGACTCTGAGAAGGTACGATTCCT - 3’ 
OATP1B1 Forward: 5’ - AAGCCACTTCTGCTTCTGTGTTT - 3’ 
Reverse: 5’ - AATTCTTAGTGAAAGGACCAGGAACT - 3’ 
Probe: 5’ - CTCAAAAATAACATCTTACTGAATCAATGCA - 3’ 
OATP1B3 Forward: 5’ - AACATGTAATTTGGACATGCAAGAC - 3’ 
Reverse: 5’ – TTGTCAGTGAAAGACCAGGAACA - 3’ 
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Probe: 5’ - CTGCTGCCAACTAACATTGCATTGATTCATT - 3’ 
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